OR10-03 Murine Bimagrumab Co-administration With Incretin Agonists Results In Additive Efficacy And Superior Quality Weight Loss In The Mouse Diet-induced Obesity Model

Disclosure: K. Nguyen: Employee; Self; Versanis Bio. X. Wang: None. D. Xu: None. L.B. Klickstein: Employee; Self; Versanis Bio. Stock Owner; Self; Novartis Pharmaceuticals. Bimagrumab is an activin type II receptor (ActRII) antagonist currently in phase 2b clinical development for the treatment of o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Kevin, Wang, Xingjuan, Xu, Deming, Klickstein, Lloyd B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Adipose Tissue, Appetite, & Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555287/
http://dx.doi.org/10.1210/jendso/bvad114.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555287/
http://dx.doi.org/10.1210/jendso/bvad114.009

Ejemplares similares